While allopurinol does not significantly reduce major adverse cardiac events (MACE) and mortality, studies have demonstrated its blood pressure-lowering properties, possibly through a direct reduction of xanthine oxidase-mediated oxidative stress, indicating the critical role of ULT in treating patients with coronary artery disease (CAD) with or without gout [41]. This evidence concerns the gene XDH and coronary artery disorder.